Evaluating sotorasib for treating brain tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of sotorasib in patients with KRAS G12C+ brain tumors who are scheduled for surgical resection or biopsy. It aims to assess the safety and efficacy of the drug, as well as how the body processes it. The trial includes adult patients with advanced brain tumors and evaluates their response to treatment while monitoring for any potential side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients ≥ 18 years of age with one or more brain tumors planned for neurosurgical resection/biopsy
* Patients with concomitant leptomeningeal metastasis are eligible provided they have parenchymal brain neoplastic disease requiring resection/biopsy
* For all cohorts: no limit on prior CNS radiation or systemic therapyKPS ≥ 60
* Life expectancy \>12 weeks
* Adequate treatment washout period from prior therapies to allow recovery from any prior treatment-related toxicities before enrollment in the judgment of the Investigator
* Adequate bone marrow, renal, hepatic, and coagulation parameters (obtained ≤7 days prior to the first day of study treatment):

  * Absolute neutrophil count (ANC) ≥1.0 × 10\^3/μL (granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1)
  * Platelet count ≥10.0x10\^4/μL. Note: Participants requiring ongoing transfusions or growth factor support to maintain platelet count ≥10.0x10\^4/μL are not eligible. (Platelet transfusion is not allowed within 1 week prior to C1D1)
  * Hemoglobin ≥ 7.0 g/dL (≥ 8 g/dL in gastric cancer / gastroesophageal cancer indications). Note: Participants requiring ongoing transfusions or growth factor support to maintain hemoglobin ≥8.0 g/dL are not eligible (Red blood cell transfusion is not allowed within 1 week prior to C1D1)
  * Creatinine clearance ≥30 mL/min, as calculated using the Cockcroft-Gault equation
  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × upper limit of normal (ULN) (\<5x ULN in participants with liver metastases)
  * Total bilirubin ≤1.5 × ULN) if no liver metastases or \<3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline

Exclusion Criteria:

* Known allergy or hypersensitivity to study treatment or any of the study drug excipients. For patients who are allergic to gadolinium-based agents may receive premedication as per institutional protocol or imaged without contrast at the discretion of the Principal Investigator; reactions will be managed per standard institutional protocol
* Multiple primary malignancies within 3 years, with the exception of:

  * adequately resected non-melanoma skin cancer
  * carcinoma in situ of the cervix
  * Smoldering pre-malignant or malignant conditions with minimal concern for CNS or extracranial progression during treatment such as CLL or MGUS based on the assessment of the treating provider
  * curatively treated in-situ disease
  * other solid tumors curatively treated
  * for patients with metastatic breast cancer: contralateral breast cancer

Where it's running

• Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Commack (Limited Protocol Activities)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering West Harrison (Limited Protocol Activities)
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Nelson Moss, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Nelson Moss, MD
• Email: mossn@mskcc.org
• Phone: 212-639-7075

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions

  A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.

  Recruiting Brigham and Women's Hospital · Boston, Massachusetts · NCT07883720

• Maintenance radiotherapy after standard glioblastoma treatment

  This study tests whether a single 2 Gy maintenance radiotherapy dose after standard treatment is safe and feasible for adults with newly diagnosed glioblastoma.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07831772

• BCB-276 CAR T therapy for DIPG in children and young adults

  This study tests BCB-276, a patient's own CAR T cells against DIPG, after standard radiation, to see if it is safe and can help extend survival.

  Recruiting at 3 sites Phase 2 BrainChild Bio, Inc · Los Angeles, California and 5 other locations · NCT07680439

• Temozolomide safety and effectiveness in adults with Grade III–IV glioma

  This study tests how safe and effective Amitzo temozolomide is in adults with Grade III or IV glioma in Iran, without a control group.

  Recruiting NanoAlvand · Tehran · NCT07675070

• Home-based vision training guided by brain imaging

  This study tests whether at‑home, image-guided visual training can improve visual field function for adults with stroke-related vision loss.

  Recruiting Georgetown University · Washington D.C., District of Columbia · NCT07635329

• Memantine and raloxifene to protect memory after brain radiation

  This study tests whether adding memantine and raloxifene to brain radiation can help adults preserve memory better than radiation alone.

  Recruiting Phase 2 The University of Texas Health Science Center at San Antonio · San Antonio, Texas · NCT07470606

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.